AstraZeneca Spies Success For Antibody To Prevent COVID-19 Infection In Vulnerable
Could Be First With Pre-Exposure Authorization
While it is likely to be fourth to market, AstraZeneca’s long-acting antibody combination could help the US battle SARS-CoV-2 in vaccine-skeptical states, data from study suggests.
You may also be interested in...
Also, Moderna completed the submission of the BLA for mRNA-1273’s FDA approval, Pfizer starts a rolling submission for a booster shot and Brii Biosciences announced data for its two-antibody antiviral cocktail, and Japan withdraws selected lots of Moderna's vaccine over contamination worries.
Identifying patients who have not mounted an immune response to SARS-CoV2 and treating them with the antibody cocktail cuts risk of death by a fifth.
GSK has poached its new chief financial officer from fashion brand Burberry, but Julie Brown’s experience at AstraZeneca and Roche will give her insights into how to lead GSK into its next phase.